Technical Analysis for RVPH - Reviva Pharmaceuticals Holdings, Inc.

Grade Last Price % Change Price Change
F 1.19 -7.03% -0.09
RVPH closed down 7.03 percent on Monday, July 1, 2024, on 29 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -7.03%
Oversold Stochastic Weakness -7.03%
Bullish Engulfing Bullish -7.03%
Oversold Stochastic Weakness -7.03%
Spinning Top Other -4.80%
Narrow Range Bar Range Contraction -4.80%
BB Squeeze Ended Range Expansion -4.80%

   Recent Intraday Alerts

Alert Time
Down 5% about 10 hours ago
New 52 Week Low about 10 hours ago
Lower Bollinger Band Support about 10 hours ago
Down 3% about 10 hours ago
Fell Below Previous Day's Low about 10 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Reviva Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, as well as for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The company is based in Cupertino, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Inflammatory Diseases Schizophrenia Psychiatric Diagnosis Psychiatry Major Depressive Disorder Stage Pharmaceutical Idiopathic Pulmonary Fibrosis Pulmonary Arterial Hypertension Pulmonary Fibrosis Chloroarenes Bipolar Disorder Pulmonary Hypertension Treatment Of Schizophrenia Piperazines

Is RVPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.8
52 Week Low 1.19
Average Volume 262,090
200-Day Moving Average 3.65
50-Day Moving Average 1.90
20-Day Moving Average 1.38
10-Day Moving Average 1.30
Average True Range 0.10
RSI (14) 28.57
ADX 46.0
+DI 10.74
-DI 34.74
Chandelier Exit (Long, 3 ATRs) 1.23
Chandelier Exit (Short, 3 ATRs) 1.50
Upper Bollinger Bands 1.57
Lower Bollinger Band 1.18
Percent B (%b) 0.03
BandWidth 28.89
MACD Line -0.17
MACD Signal Line -0.20
MACD Histogram 0.0255
Fundamentals Value
Market Cap 33.22 Million
Num Shares 27.9 Million
EPS -1.68
Price-to-Earnings (P/E) Ratio -0.71
Price-to-Sales 0.00
Price-to-Book 69.86
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.33
Resistance 3 (R3) 1.34 1.31 1.30
Resistance 2 (R2) 1.31 1.28 1.30 1.29
Resistance 1 (R1) 1.25 1.25 1.24 1.24 1.29
Pivot Point 1.22 1.22 1.21 1.21 1.22
Support 1 (S1) 1.16 1.19 1.15 1.15 1.09
Support 2 (S2) 1.13 1.16 1.12 1.09
Support 3 (S3) 1.07 1.13 1.08
Support 4 (S4) 1.06